Context:In recent days, we have come across an increase incidence of dry mouth as a side effects of drugs and in order to bring an awareness about a simple non- invasive method to increase the salivary flow, we have used TENS which in many way is beneficial to patients with metabolic disorders.Aims and Objectives:The aim is to assess the effectiveness of transcutaneous electrical nerve stimulation on salivary gland function in patients with hyposalivation.Subjects and Methods:The present study included total of 25 subjects with complaint of hyposalivation. Written informed consent was obtained from all the participants. Subjects with pacemakers, autoimmune diseases, pregnancy, and history of salivary gland pathology were excluded from the study. Subjects were asked to refrain from eating, drinking, chewing gum, smoking, and oral hygiene procedures for at least 1 h before the appointment. Unstimulated saliva was collected using modified Carlson Crittenden cup placed over the Stenson's duct bilaterally for 5 min and measured. TENS pads were placed over the parotid region and were activated. The intensity control switch was adjusted for patient's comfort. The intensity was turned up 1 increment at a time at 5 s intervals until the optimal intensity level was reached and stimulated saliva was then collected for 5 min using the modified Carlson Crittenden cup and measured. Any increase in parotid salivary flow (SF) with electrostimulation was considered a positive finding.Statistical Analysis Used:A paired t-test, evaluating mean changes in stimulated versus unstimulated SF rates, was applied to look for statistically significant differences using PASW 18.0 for Windows. An independent sample t-test was performed to note difference between genders.Results:There was significant increase in parotid SF in 19 of 25 patients after transcutaneous electrical nerve stimulation. Males showed more salivary secretion when compared to females.Conclusions:From the results of the study and within limitations of the study, it can be concluded that TENS was effective in increasing the SF rate in hyposalivatory patients with residual saliva. TENS was less effective in patients who are under xerogenic drugs. Thus, TENS may be an ever-growing armamentarium in the management of salivary gland hypofunction when other therapies have failed or are contraindicated.
Background: Parkinson's disease is the second most common neurodegenerative disorder which affects around four million people globally.Many of the signs of Parkinson's disease are found in the head and neck. The typical "masklike" facial appearance with infrequent blinking and lack of expression is caused by bradykinesis.. Abnormalities in oral behaviour, such as purposeless chewing, grinding, and sucking movements, are also well recognized in patients with Parkinson's disease.
Aim and Objectives:The aim of this study is to assess the overall oral health status of the patients with Parkinson's disease and to analyze the impact of Parkinson's disease on the oral cavity of the individuals surviving with the disease.
Materials and Methods:The study sample included 50 Parkinson's disease patients. The patients of all age groups and both genders were included.Results: Out of fifty patients. majority of the patient s were above 60 yrs. 6% of the patients reported with Positive family history of Parkinson's diseases.14% of the patients had gross facial asymmetry, 68% of the patients showed dryness of mouth.8% of the patients suffered loss of taste.14% of the patients showed hyper salivation. 54% of the patients showed gingivitis. And 76% of the patients were found having periodontitis.
Conclusion:Treatment for oral and dental problems of Parkinson's disease affected patients is mandatory. Treatment can be done by supplementing artificial saliva for dryness of mouth, dental fillings for dental caries, periodic scaling for periodontal problems, oral rehabilitation measures and regular dental check up
Background
Iron deficiency anemia is one of the important public health problems in developing countries among the women of reproductive age group. Hemocare formulation plays a significant role in Iron deficiency anemia because of its Iron content. The present study aimed to investigate the effect of Hemocare Syrup and Hemocare XT Tablets compared with placebo on Hemoglobin Levels in Iron Deficiency Anemia among Women of Reproductive Age.
Methods
A prospective, interventional, randomized, open label, placebo controlled trial has been conducted with 126 patients. Eligible patients randomly received either Placebo 100 mg or Hemocare XT Tablet 100 mg or 10 ml of Hemocare Syrup once daily in the same manner for 4 weeks. Hemoglobin values were documented at the end of 15th day, 21st day and 30th day.
Results
The baseline hemoglobin values were compared with each follow up and statistically significant difference was found at the end of 30th day of Hemocare Syrup and Hemocare XT treatment (P < 0.05) but there was no significant difference observed in the placebo group. The study results revealed that 30 days treatment of Hemocare Syrup and Hemocare XT Tablets increases the Hemoglobin levels to 12.46 ± 0.44 g/dl and 12.90 ± 0.98 g/dl from 9.08 ± 2.54 g/dl and 9.68 ± 2.04 g/dl respectively.
Conclusion
Hemocare Syrup and Hemocare XT Tablets treatment showed clinically significant improvement in hemoglobin levels from the baseline and placebo group.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.